PDE4D targeting enhances anti-tumor effects of sorafenib in clear cell renal cell carcinoma and attenuates MAPK/ERK signaling in a CRAF-dependent manner

Clear cell renal cell carcinoma (ccRCC) is the most lethal form of kidney cancer and effective treatment regimens are yet to be established. Tyrosine kinase inhibitors (TKI) have widely been used as ccRCC therapeutics, but their efficacy is limited due to accompanying resistance mechanisms. Previous...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Minghua, Nawalaniec, Karol, Ajay, Amrendra K., Luo, Yueming, Moench, Romana, Jin, Yanfei, Xiao, Sheng, Hsiao, Li-Li, Waaga-Gasser, Ana Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866901/
https://www.ncbi.nlm.nih.gov/pubmed/35196602
http://dx.doi.org/10.1016/j.tranon.2022.101377

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866901/
https://www.ncbi.nlm.nih.gov/pubmed/35196602
http://dx.doi.org/10.1016/j.tranon.2022.101377

Ejemplares similares